Bio TiumBio expedites immunotherapy TU2218 trials in US, Korea TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2... Kim Chan

Media coverage

• Title	Bio TiumBio expedites immunotherapy TU2218 trials in US, Korea TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2... Kim Chan
  Media name/outlet	Korea Biomedical Review
  Date	22/3/15
  URL	ct.moreover.com/?a=47273532815&p=1gw&v=1&x=xOthcBgG7N3bVdfiEqqH3g
  Persons	Soon-Il An